RARE – Ultragenyx Pharmaceutical Inc.

RARE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

14.98

Margin Of Safety %

Put/Call OI Ratio

2.18

EPS Next Q Diff

0.17

EPS Last/This Y

1.64

EPS This/Next Y

7.32

Price

25.92

Target Price

52.84

Analyst Recom

1.4

Performance Q

Upside

-888.9%

Beta

0.32

Ticker: RARE

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	RARE	32.01	1.90	0.69	55423
2026-07-15	RARE	31.69	1.90	1.57	55463
2026-07-16	RARE	30.23	1.90	0.49	55464
2026-07-17	RARE	29.29	1.90	4.64	55490
2026-07-20	RARE	28.51	1.98	58.80	53439
2026-07-21	RARE	28.6	2.69	1.99	66517
2026-07-22	RARE	27.65	2.62	11.53	72552
2026-07-23	RARE	27.03	2.73	7.19	77647
2026-07-24	RARE	26.91	2.73	9.36	83364
2026-07-27	RARE	26.9	2.67	38.68	81991
2026-07-28	RARE	25.95	2.74	0.59	83666
2026-07-29	RARE	24.88	2.74	0.52	83699
2026-07-30	RARE	26.04	2.74	0.55	83734
2026-07-31	RARE	24.9	2.57	0.70	86629
2026-08-03	RARE	25.1	2.57	0.19	86625
2026-08-04	RARE	25.86	2.56	0.38	86766
2026-08-05	RARE	24.93	2.56	1.53	86779
2026-08-06	RARE	25.84	2.22	2.07	86445
2026-08-07	RARE	25.91	2.18	0.94	96259
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	RARE	32.01	1.6	-	-4.42
2026-07-15	RARE	31.67	1.6	-	-4.42
2026-07-16	RARE	30.19	1.6	-	-4.24
2026-07-17	RARE	29.27	1.6	-	-4.24
2026-07-20	RARE	28.53	1.6	-	-4.24
2026-07-21	RARE	28.60	1.6	-	-4.24
2026-07-22	RARE	27.68	1.6	-	-4.24
2026-07-23	RARE	27.03	1.6	-	-4.24
2026-07-24	RARE	26.89	14.8	-	-4.19
2026-07-27	RARE	26.88	14.8	-	-4.19
2026-07-28	RARE	25.93	14.8	-	-4.19
2026-07-29	RARE	25.00	14.8	-	-4.19
2026-07-30	RARE	26.05	14.8	-	-4.19
2026-07-31	RARE	24.90	14.8	-	-4.19
2026-08-03	RARE	25.00	14.8	-	-4.19
2026-08-04	RARE	25.00	14.8	-	-4.19
2026-08-05	RARE	24.95	14.8	-	-4.19
2026-08-06	RARE	25.84	14.8	-	-4.19
2026-08-07	RARE	25.92	14.8	-	-4.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	RARE	-1.60	-0.63	18.09
2026-07-15	RARE	-1.60	-0.63	18.09
2026-07-16	RARE	-1.60	-0.63	18.09
2026-07-17	RARE	-1.60	-0.63	18.09
2026-07-20	RARE	-1.60	-0.95	18.09
2026-07-21	RARE	-1.60	-0.95	18.09
2026-07-22	RARE	-1.60	-0.95	18.09
2026-07-23	RARE	-1.60	-0.95	18.09
2026-07-24	RARE	-1.60	-0.95	18.09
2026-07-27	RARE	-1.60	-0.94	14.98
2026-07-28	RARE	-1.60	-0.94	14.98
2026-07-29	RARE	-1.60	-0.94	14.98
2026-07-30	RARE	-1.60	-0.94	14.98
2026-07-31	RARE	-1.60	-0.94	14.98
2026-08-03	RARE	-1.60	0.01	14.98
2026-08-04	RARE	-1.64	0.01	14.98
2026-08-06	RARE	-1.64	0.01	14.98
2026-08-07	RARE	-1.64	0.01	14.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.9

Avg. EPS Est. Current Quarter

-1

Avg. EPS Est. Next Quarter

-0.73

Insider Transactions

-1.64

Institutional Transactions

0.01

Beta

0.32

Average Sales Estimate Current Quarter

181

Average Sales Estimate Next Quarter

185

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

75.2

Max Drawdown 5-Year %

-81.9

Target Price

52.84

P/E

Forward P/E

PEG

P/S

3.56

P/B

P/Free Cash Flow

EPS

-5.84

Average EPS Est. Cur. Y

-4.19

EPS Next Y. (Est.)

3.13

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-81.79

Relative Volume

1.74

Return on Equity vs Sector %

174.1

Return on Equity vs Industry %

190.1

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.06

EBIT Estimation

◆ RARE Healthcare

$25.91

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

10/20

Pullback

18/25

Volume

3/15

Valuation

12/20

TP/AR

2/10

Options

1/10

RSI

Range 1M

13.9%

Sup Dist

3.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

18/30

Estimates

3/20

Inst/Vol

5/15

Options

2/10

EPS Yr

26.7%

52W%

34.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +260.3% upside

Quality

8/30

Valuation

18/30

Growth

12/25

Stability

8/10

LT Trend

2/5

Upside

+260.3%

Quality

RARE — P/E HistoricalBiotechnology

Ultragenyx Pharmaceutical Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1371

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

RARE

Latest News

—

Caricamento notizie per RARE…

stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today

news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance

stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market

stock prices RARE premarket after hours

ticker RARE fair value insiders trading

RARE – Ultragenyx Pharmaceutical Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RARE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y